12:00 AM
Jan 09, 2015
 |  BC Extra  |  Clinical News

Argos falls on Phase IIb miss in HIV

Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy interruption vs. placebo in a Phase IIb trial to treat HIV.

AGS-004 is an autologous dendritic cell immunotherapy transfected with the patient's viral RNA antigens.

On a conference call, CSO and...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >